1. Introduction {#sec0005}
===============

Androgen deprivation is a major therapeutic option for the treatment of advanced/metastatic prostate cancer, however, most responders eventually develop resistance to this therapy. Second-line systemic treatments, including new types of androgen receptor signaling inhibitors, glucocorticoids, and cytotoxic agents, have been shown to have a survival benefit in patients with castration-resistant prostate cancer (CRPC); however, the efficacy of these drugs is often short-lived [@bib0005], [@bib0010], [@bib0015]. Thus, new therapeutic targets and clinical markers are urgently required.

The atypical protein kinase C λ/ι (aPKCλ/ι) is involved in several signal transduction pathways and the establishment of epithelial cell polarity [@bib0020]. Previous studies have suggested that the deregulation of aPKCλ/ι is associated with the pathogenesis and progression of various types of neoplasms [@bib0025], [@bib0030], [@bib0035]. Recently, the overexpression of aPKCλ/ι and its gene amplification have been found in lung and ovarian cancers [@bib0020], [@bib0040], [@bib0045], [@bib0050]. In addition, a higher aPKCλ/ι expression has been shown to correlate with poorer outcomes in patients with metastatic prostate cancer [@bib0055]. The present study performed immunohistochemical analyses of aPKCλ/ι in initially metastatic prostate cancer to reveal the impact of aPKCλ/ι expression on the prognosis in initially advanced prostate cancer.

2. Case presentation {#sec0010}
====================

A total of 43 patients with prostate cancer and associated metastasis to the lymph node and/or bone were analyzed in this study. This study was approved by the Yokohama City University Hospital Institutional Review Board and written informed consent was obtained from all enrolled patients. We performed immunohistochemistry in prostate biopsy specimens using a primary antibody raised against aPKCι (dilution 1:50, BD Biosciences, San Jose, CA, USA), as previously described [@bib0060]. The Kaplan-Meier product limit estimator was used to estimate the cancer-specific survival (CSS). The survival duration was defined as the time between the pathological diagnosis and death. The results were compared using a log-rank test. *P* values of \<0.05 were considered to indicate statistical significance. We adhered to the PROCESS criteria for this study [@bib0065], [@bib0070].

Positive signals for aPKC were detected in both the nuclei and cytoplasm of epithelial/carcinoma cells. Because of higher expression of aPKCλ/ι, we evaluated the nuclear expression in our analysis. Overall, aPKCλ/ιwas positive in 32 (74.4%) of 43 prostate cancer specimens. \[[Fig. 1](#fig0005){ref-type="fig"}\] In 25 (78.1%) of 32 aPKCλ/ι-positive cases, similar levels of its expression were seen in non-neoplastic epithelial cells. There were no significant correlations between the aPKCλ/ι expression and CSS or in the clinicopathological features, including the Gleason score, pT stage, and the metastatic site. \[[Fig. 2](#fig0010){ref-type="fig"}\] We previously reported that aPKCλ/ι was highly expressed in CRPCs in comparison to tumors that had no undergone androgen deprivation therapy [@bib0075], but the current staining did not reveal a significant correlation between the aPKCλ/ι expression and CSS.Fig. 1Immunohistochemical staining of aPKCλ/ι. (a: Nuclear, b: Cytoplasmic, c: Nuclear and Cytoplasic, expression).Fig. 1Fig. 2The CSS of patients with metastatic prostate cancer according to the aPKCλ/ι expression in primary tumors.Fig. 2

3. Discussion {#sec0015}
=============

This study is a first study to investigate the aPKCλ/ι expression in metastatic hormone sensitive prostate cancer. The current study is associated with a limitation regarding its small sample size. As a result, we could not definitively confirm the lack of any association between aPKCλ/ι expression in the initial biopsy specimens and the prognosis. aPKCλ/ι might contribute to tumor progression, such as the transition to CRPC rather than the aggressiveness of hormone-naive cancer. In summary, this is the first study to assess the aPKCλ/ι expression in primary prostate cancer with metastatic disease. We found no strong association between the aPKCλ/ι expression and the prognosis of these patients.
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